பால் ஹாப்பர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from பால் ஹாப்பர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In பால் ஹாப்பர் Today - Breaking & Trending Today
The clinical-stage immune-oncology company will use the funds to support work across its three novel technology platforms and bolster its clinical. ....
Meme-stock fever spreads to more companies on ASX afr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from afr.com Daily Mail and Mail on Sunday newspapers.
All the latest ASX news from the Markets Live team. Reporting on the ASX200 today, Australia’s top stocks, companies, iron ore price, gold price, the Aussie dollar (AUD), Bitcoin, reporting season, and breaking business news ....
Imugene embarks on $95 million capital raise to fund clinical pipeline into 2025 The biotech’s multi-million-dollar capital raise will support development opportunities across its clinical portfolio over the next four years. Imugene has set out to raise $95 million to support its clinical pipeline. Imugene Limited (ASX:IMU, OTC:IUGNF) has embarked on a A$95 million capital raise, establishing a funding runway that will financially support its clinical trial pipeline through 2025. The Australia-headquartered biotech has already received firm commitments to raise A$90 million through a placement executed at 30 cents per share and now hopes to secure a further A$5 million via a share purchase plan (SPP) at the same price. ....
) Chimeric Therapeutics licenses novel CAR T cell therapy with “transformative potential” from the University of Pennsylvania Thanks to an exclusive licensing agreement with “a powerhouse in CAR T innovation”, Chimeric believes it is a step closer to bringing cell therapy to life for cancer patients. Chimeric Therapeutics will develop and commercialise a novel immunotherapy from one of the world’s pre-eminent cell therapy centres. Chimeric Therapeutics Ltd has licensed a novel cancer therapy for solid tumours from a world-renowned cell therapy centre. Through an agreement with the University of Pennsylvania, the ASX-listed biotech will exclusively develop and commercialise the CDH17 chimeric antigen receptor T cell (CAR T) therapy. ....